183 related articles for article (PubMed ID: 28960387)
1. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients.
Franken LG; de Winter BCM; Masman AD; van Dijk M; Baar FPM; Tibboel D; Koch BCP; van Gelder T; Mathot RAA
Br J Clin Pharmacol; 2018 Feb; 84(2):320-330. PubMed ID: 28960387
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
[TBL] [Abstract][Full Text] [Related]
3. Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?
Franken LG; Masman AD; de Winter BCM; Baar FPM; Tibboel D; van Gelder T; Koch BCP; Mathot RAA
Br J Clin Pharmacol; 2017 Aug; 83(8):1701-1712. PubMed ID: 28177137
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacodynamics of midazolam administered by target controlled infusion in SICU patients after CABG surgery.
Somma J; Donner A; Zomorodi K; Sladen R; Ramsay J; Geller E; Shafer SL
Anesthesiology; 1998 Dec; 89(6):1430-43. PubMed ID: 9856718
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients.
Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
Eur J Clin Pharmacol; 2006 Mar; 62(3):185-94. PubMed ID: 16425056
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model.
Barr J; Zomorodi K; Bertaccini EJ; Shafer SL; Geller E
Anesthesiology; 2001 Aug; 95(2):286-98. PubMed ID: 11506097
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
Fromm MF; Schwilden H; Bachmakov I; König J; Bremer F; Schüttler J
Eur J Clin Pharmacol; 2007 Dec; 63(12):1129-33. PubMed ID: 17786417
[TBL] [Abstract][Full Text] [Related]
8. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
9. Bispectral Index Monitoring in Terminally Ill Patients: A Validation Study.
Masman AD; van Dijk M; van Rosmalen J; Blussé van Oud-Alblas HJ; Ista E; Baar FP; Tibboel D
J Pain Symptom Manage; 2016 Aug; 52(2):212-220.e3. PubMed ID: 27220943
[TBL] [Abstract][Full Text] [Related]
10. Midazolam therapeutic drug monitoring in intensive care sedation: a 5-year survey.
Bremer F; Reulbach U; Schwilden H; Schüttler J
Ther Drug Monit; 2004 Dec; 26(6):643-9. PubMed ID: 15570189
[TBL] [Abstract][Full Text] [Related]
11. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
Br J Clin Pharmacol; 2004 Feb; 57(2):135-45. PubMed ID: 14748812
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery.
Peeters MY; Prins SA; Knibbe CA; Dejongh J; Mathôt RA; Warris C; van Schaik RH; Tibboel D; Danhof M
Anesthesiology; 2006 Dec; 105(6):1135-46. PubMed ID: 17122576
[TBL] [Abstract][Full Text] [Related]
13. Assessment of depth of midazolam sedation using objective parameters.
Haberthür C; Lehmann F; Ritz R
Intensive Care Med; 1996 Dec; 22(12):1385-90. PubMed ID: 8986490
[TBL] [Abstract][Full Text] [Related]
14. Palliative Sedation for the Terminally Ill Patient.
Garetto F; Cancelli F; Rossi R; Maltoni M
CNS Drugs; 2018 Oct; 32(10):951-961. PubMed ID: 30259395
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting.
Zomorodi K; Donner A; Somma J; Barr J; Sladen R; Ramsay J; Geller E; Shafer SL
Anesthesiology; 1998 Dec; 89(6):1418-29. PubMed ID: 9856717
[TBL] [Abstract][Full Text] [Related]
16. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.
Porzio G; Aielli F; Verna L; Micolucci G; Aloisi P; Ficorella C
Support Care Cancer; 2010 Jan; 18(1):77-81. PubMed ID: 19343368
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of haloperidol in terminally ill adult patients.
Franken LG; Mathot RAA; Masman AD; Baar FPM; Tibboel D; van Gelder T; Koch BCP; de Winter BCM
Eur J Clin Pharmacol; 2017 Oct; 73(10):1271-1277. PubMed ID: 28681176
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.
Franken LG; de Winter BC; van Esch HJ; van Zuylen L; Baar FP; Tibboel D; Mathôt RA; van Gelder T; Koch BC
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):669-80. PubMed ID: 27081769
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological Treatment in End-of-Life Sedation].
Domínguez Álvarez R; Mejías Estéve M; Galán González-Serna JM
Rev Enferm; 2017 Feb; 40(2):31-38. PubMed ID: 30272405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
